Étiquette : antidépresseur

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition, Bernhard Luscher et al., 2020

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Fenga, Sarah J. Jefferson Advances in Pharmacology, 2020 doi : 10.1016/bs.apha.2020.03.002   Contents 1. Introduction 3 2. Molecular targets of subanesthetic ketamine and its metabolites 6 3. Insights from ketamine indicate a key role for reduced GABAergic inhibition in the pathophysiology of major depression 7 3.1 Antidepressant efficacy of ketamine is controlled by imbalances between neural excitation and inhibition 7 3.2 Chronic imbalances of neural excitation and inhibition lead to homeostatic downregulation of glutamatergic synapses that compromises normal neuronal communication 9 3.3 Chronic imbalances between neural excitation and inhibition lead to defects in GABAergic inhibition that delimit spontaneous recovery from [...]

Lire la suite

Les effets antidépresseurs de la kétamine élucidés, Florence Rosier, Le Monde, 16 avril 2019

Les effets antidépresseurs de la kétamine élucidés Utilisée de longue date comme anesthésique, cette molécule vient d’être autorisée comme antidépresseur aux Etats-Unis. Par Florence Rosier Publié le 16 avril 2019 à 06h00 - https://www.lemonde.fr/sciences/article/2019/04/16/les-effets-antidepresseurs-de-la-ketamine-elucides_5450737_1650684.html   La kétamine est une molécule à surprises. Et pas seulement pour ceux qui recherchent ses effets hallucinogènes en la détournant de ses applications médicales. Depuis les années 1970, elle est largement utilisée comme anesthésique à usage humain ou vétérinaire. Mais elle est aussi dotée de puissants effets antidépresseurs, découverts voici plus de vingt ans. Or, ceux-ci viennent d’être doublement reconnus : au plan réglementaire, par la toute-puissante agence américaine du médicament (FDA) ; [...]

Lire la suite

Confinement et cannabis, cachez cette addiction que le gouvernement ne saurait voir, Jean-Yves Nau, Slate.fr, 2 avril 2020

Confinement et cannabis, cachez cette addiction que le gouvernement ne saurait voir Jean-Yves Nau — 2 avril 2020 à 7h00 http://www.slate.fr/story/189123/addictions-cannabis-confinement-coronavirus-deni-consequences-dependance Tabac, alcool et produits de vapotage n'ont heureusement pas été interdits. Mais il va falloir compter avec les multiples conséquences de la pénurie en cannabis. «Une dépendance grave à une substance licite vaut toujours mieux qu'une dépendance de moindre gravité à une substance interdite», déplore le Dr William Lowenstein, président de SOS Addictions. | realworkhard, ponce_photography et gjbmiller via Pixabay Il croyait très bien faire. Lundi 23 mars, Ziad Khoury, préfet de l'Aisne, prenait un arrêté interdisant toutes les ventes d'alcool à emporter dans l'ensemble du [...]

Lire la suite

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline, Allison A. Feduccia et al., 2019

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer and Rick Doblin Frontiers in Psychiatry, 2019, Volume 10, Article 650. doi: 10.3389/fpsyt.2019.00650   Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and lifethreatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4 methylenedioxymethamphetamine [...]

Lire la suite

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression, Paulo R. Shiroma et al., 2014

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Paulo R. Shiroma, C. Sophia Albott, Brian Johns, Paul Thuras, Joseph Wels and Kelvin O. Lim The International Journal of Neuropsychopharmacology, 2014, Volume 17, Issue 11, 1805–1813, Doi : 10.1017/S1461145714001011   Abstract The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid anti-depressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive aspects in TRD has started to be explored. This study aims to (1) examine baseline neurocognitive performance and change in severity of depressive symptoms through six ketamine infusions, (2) examine the neurocognitive effects after completion of serial infusions and whether changes were associated to [...]

Lire la suite

Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada, Elena ARGENTO et al., 2019

Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada Elena ARGENTO, Rielle CAPLER, Gerald THOMAS, Philippe LUCAS & Kenneth W. TUPPER Drug and Alcohol Review, 2019 Doi : 10.1111/dar.12985   Abstract Introduction and Aims. A previous observational study of ayahuasca-assisted therapy demonstrated statistically significant reductions in self-reported problematic cocaine use among members of an Indigenous community in Canada. This paper aims to qualitatively explore the impact of ayahuasca assisted therapy on addiction and other substance use-related outcomes and elucidate the lived experiences of participants. Design and Methods. Qualitative interviews were conducted with 11 adult Indigenous participants of the ayahuasca-assisted [...]

Lire la suite

Translational evidence for ayahuasca as an antidepressant : what’s next ?

Translational evidence for ayahuasca as an antidepressant : what’s next ? Rafael Guimaraes dos SANTOS, José Carlos BOUSO British Journal of Psychiatry, 2019, 41, (4), 275-276. Doi : 10.1590/1516-4446-2019-4104   Depression is among the most important contributors to global disability and suicidal deaths. Available antidepressants are usually selective inhibitors of serotonin and norepinephrine uptake, which need weeks of daily intake before therapeutic effects appear, have limited efficacy for many patients, and induce significant adverse reactions after prolonged use. Therefore, recent research has focused on finding new antidepressant compounds that are fast-acting, more effective, and less toxic. The article recently published by da Silva et al. in the [...]

Lire la suite

Cannabis Use Rising Faster Among Depressed Americans, Lisa Rapaport, Medscape, 2019.

Cannabis Use Rising Faster Among Depressed Americans Lisa Rapaport  Medscape - Dec 26, 2019. https://www.medscape.com/viewarticle/923160?nlid=133282_2052&src=WNL_mdplsnews_200103_mscpedit_psyc&uac=292598PZ&spon=12&impID=2232271&faf=1 (Reuters Health) - Regular cannabis use has risen more quickly among people with depression, and they're less likely to perceive it as risky, compared with people who aren't depressed, a U.S. study suggests. Researchers examined data collected from a total of almost 729,000 people aged 12 years and older between 2005 and 2017, including any prior-month cannabis use and any depression experienced over the previous year. By the final year of the study, about 19% of people with depression reported at least some cannabis use, compared with 8.7% of individuals without a recent history of [...]

Lire la suite

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis, Alexander B. Belser et al., 2017

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp   Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]

Lire la suite